They should understand that semaglutide is typically a long-term therapy, and discontinuation may result in weight regain
I respectfully encourage the FDA to work collaboratively with physicians, researchers, pharmacists, and patient advocates to preserve safe access to therapeutic peptides while maintaining the highest standards of quality and patient protection
Those frustrating issues crop up when your metabolic health needs attention and giving your body the right kind of support can really turn things around
J., Kovatchev, B., & Zinman, B
118 (11.7%) did not complete the trial In adults with established CVD either overweight or obesity, Safety data from the SELECT trial with Wegovy 2.4 mg Safety was evaluated in a trial of 17,604 patients 5 Safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest